Isogenica Discovery on Target PDF Poster

Sep 23, 2021

Isogenica is excited to announce its attendance at Discovery on Target 2021 September 27-30th

Isogenica’s Associate Director of Antibody Alliances, Marion Cubitt, will be attending Discovery on Target 2021 virtually on September 27-30th. 

Marion will be presenting the latest Isogenica VHH data on Synthetically-Derived PD-1 Antagonising VHHs Bind in Monomer and Multimer Formats to PD-L1-Expressing Breast Cancer Cells.

Do not miss out on the opportunity to have a live conversation with Marion at the

VIRTUAL POSTER CHAT (13:15 – 13:45 EDT, 29th Sept)

to discuss VHH applications in multiple formats such as bi-specifics and how you could apply Isogenica’s technology in your projects.

Further Information

Isogenica has developed LlamdA™ (single domain VHH) therapeutic antibodies from its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.  Over the last four years Isogenica has entered into eight significant partnerships, leveraging its libraries, technologies and expertise to build a broad pipeline of programs that are now advancing into pre-clinical and early clinical development with our partners.”


Mandeep Sehmi,
Business Development

T +44 1799 533 680